Citations 2
Level I PD‐MCI Using Global Cognitive Tests and the Risk for Parkinson's Disease Dementia
Boel, Judith A., Bie, Rob M.A. de , Schmand, Ben , Dalrymple‐Alford, John C. , Adler, Charles H. , Goldman, Jennifer G. , Tröster, Alexander I. , Geurtsen, Gert J. , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's, Halliday, Glenda M. , Antonini, Angelo , Lewis, Simon J.G. , Biundo, Roberta , Segura, Bàrbara , Williams‐Gray, Caroline H. , de Bie, Rob M A , Adler, C H , Geurtsen, Gert J , Halliday, Glenda , Goldman, Jennifer G , Antonini, Angelo , Dalrymple-Alford, John C , Lewis, Simon J G , Williams-Gray, Caroline H , Segura, Barbara , Marras, Connie , Burn, David J. , Litvan, Irene , Disease, MDS Study Group Mild Cognitive Impairment in Parkinson's
Movement Disorders Clinical Practice | April 5, 2022 | Volume: 9 | Issue: 4 | Pages: 479-483
ABSTRACTBackgroundThe criteria for PD‐MCI allow the use of global cognitive tests. Their predictive value for conversion from PD‐MCI to PDD, especially compared to comprehensive neuropsychological assessment, is unknown.MethodsThe MDS PD‐MCI Study Group combined four datasets containing global cognitive tests as well as a comprehensive neuropsychological assessment to define PD‐MCI (n = 467). Risk for developing PDD was examined using a Cox model. Global cognitive tests were compared to neuropsychological test batteries (Level I&II) in determining risk for PDD.ResultsPD‐MCI based on a global cognitive test (MMSE or MoCA) increases the hazard for developing PDD (respectively HR = 2.57, P = 0.001; HR = 4.14, P = <0.001). The C‐statistics for MMSE (0.72) and MoCA (0.70) were lower than those based on neuropsychological tests (Level I = 0.82; Level II = 0.81). Sensitivity, specificity and diagnostic accuracy balance was best in Level II.ConclusionMMSE and MoCA predict conversion to PDD. However, Level II neuropsychological assessment seems the preferred assessment for PD‐MCI.
Detecting Mild Cognitive Deficits in Parkinson's Disease: Comparison of Neuropsychological Tests
Hoogland, Jeroen , Wanrooij, Lennard L. van , Boel, Judith A., Goldman, Jennifer G. , Stebbins, Glenn T. , Dalrymple‐Alford, John C. , Junqué, Carme , Pedersen, Kenn Freddy , Mollenhauer, Brit , Zabetian, Cyrus P. , Eslinger, Paul J. , Lewis, Simon J.G. , Wu, Ruey‐Meei , Klein, Martin , Rodríguez‐Oroz, María , Cammisuli, Davide Maria , Biundo, Roberta , Bie, Rob M.A. de , Schmand, Ben , Tröster, Alexander I. , Burn, David J. , Filoteo, J. Vincent , Geurtsen, Gert J. , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Goldman, Jennifer G , Dalrymple-Alford, John C , Lewis, Simon J G , Zabetian, Cyrus P , de Bie, Rob M A , Geurtsen, Gert J , Junque, Carme , Marras, Connie , Adler, Charles H. , Barone, Paolo , Litvan, Irene , Weintraub, Daniel , Disease”, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson, Wu, Ruey-Meei
Movement Disorders | September 14, 2018 | Volume: 33 | Issue: 11 | Pages: 1750-1759
AbstractBackground: Numerous neuropsychological tests and test versions are used in Parkinson's disease research, but their relative capacity to detect mild cognitive deficits and their comparability across studies are unknown. The objective of this study was to identify neuropsychological tests that consistently detect cognitive decline in PD across studies.Methods: Data from 30 normed neuropsychological tests across 20 international studies in up to 2908 nondemented PD patients were analyzed. A subset of 17 tests was administered to up to 1247 healthy controls. A 2‐step meta‐analytic approach using standardized scores compared performance in PD with normative data.Results: Pooled estimates of the differences between PD and site‐specific healthy controls identified significant cognitive deficits in PD patients on 14 test scores across 5 commonly assessed cognitive domains (attention or working memory, executive, language, memory, and visuospatial abilities), but healthy control performance was statistically above average on 7 of these tests. Analyses based on published norms only, as opposed to direct assessment of healthy controls, showed high between‐study variability that could not be accounted for and led to inconclusive results.Conclusions: Normed neuropsychological tests across multiple cognitive domains consistently detect cognitive deficits in PD when compared with site‐specific healthy control performance, but relative PD performance was significantly affected by the inclusion and type of healthy controls versus the use of published norms only. Additional research is needed to identify a cognitive battery that can be administered in multisite international studies and that is sensitive to cognitive decline, responsive to therapeutic interventions, and superior to individual cognitive tests. © 2018 International Parkinson and Movement Disorder Society